Devendra Hiwase

• Appointments

  Date	Position	Institution name
  2021 - ongoing	Clinical Associate Professor	The University of Adelaide

• Language Competencies

  Language	Competency
  English	Can read, write, speak, understand spoken and peer review

• Research Interests

  Haematological Tumours Haematology

• Journals

  Year	Citation
  2024	Tefferi, A., Fleti, F., Chan, O., Al Ali, N. H., Al-Kali, A., Begna, K. H., . . . Komrokji, R. (2024). TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q). British Journal of Haematology, 204(4), 1243-1248. DOI Scopus1 Europe PMC1
  2024	McQuilten, Z., Heritier, S., Fox, L., Fox, V., Young, L., Blombery, P., . . . Wood, E. (2024). Efficacy and safety of avatrombopag in combination with immunosuppressive therapy in treatment-naïve and relapsed/refractory severe aplastic anaemia: Protocol for the DIAAMOND-Ava-FIRST and DIAAMOND-Ava-NEXT Bayesian Optimal Phase II trials. BMJ Open, 14(1), 11 pages. DOI
  2024	Kok, C. H., Yeung, D. T., & Hiwase, D. K. (2024). Special Issue “Advances in Molecular Pathogenesis and Targeted Therapies for Myeloid Neoplasms”. International Journal of Molecular Sciences, 25(4), 5 pages. DOI
  2024	Hong, L. E., Wechalekar, M. D., Kutyna, M., Small, A., Lim, K., Thompson-Peach, C., . . . Hiwase, D. K. (2024). IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation. Blood, blood.2023023593. DOI
  2023	Thomas, D., Wu, M., Nakauchi, Y., Zheng, M., Thompson-Peach, C. A., Lim, K., . . . Majeti, R. (2023). Dysregulated lipid synthesis by oncogenic IDH1 mutation is a targetable synthetic lethal vulnerability. Cancer Discovery, 13(2), 496-515. DOI Scopus13 WoS7 Europe PMC9
  2023	Hiwase, D. K., Hahn, C. N., Tran, E. N. H., Chhetri, R., Baranwal, A., Al-Kali, A., . . . Shah, M. V. (2023). TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype. Blood, 141(9), 1087-1091. DOI Scopus9 WoS7 Europe PMC6
  2023	Fleti, F., Chan, O., Singh, A., Abdelmagid, M. G., Al-Kali, A., Elliott, M. A., . . . Tefferi, A. (2023). TP53 mutations and variant allele frequency in myelodysplastic syndromes with del(5q): A Mayo-Moffitt study of 156 informative cases. American Journal of Hematology, 98(4), E76-E79. DOI Scopus2 WoS1 Europe PMC2
  2023	de Botton, S., Fenaux, P., Yee, K., Récher, C., Wei, A. H., Montesinos, P., . . . Cortes, J. (2023). Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. Blood Advances, 7(13), 3117-3127. DOI Scopus26 WoS11 Europe PMC13
  2023	Kutyna, M. M., Loone, S., Saunders, V. A., White, D. L., Kok, C. H., & Hiwase, D. K. (2023). Solute Carrier Family 29A1 Mediates In Vitro Resistance to Azacitidine in Acute Myeloid Leukemia Cell Lines. International Journal of Molecular Sciences, 24(4), 3553-1-3553-14. DOI
  2023	Montarello, N., Leslie, A., Chhetri, R., Friel, O., Singhal, D., Ross, D. M., . . . Hiwase, D. K. (2023). Personalized risk model for predicting risk of acute coronary syndrome in patients with myelodysplastic syndromes.. Blood Advances, 7(13), 3032-3035. DOI
  2023	Baranwal, A., Chhetri, R., Yeung, D., Clark, M., Shah, S., Litzow, M. R., . . . Shah, M. V. (2023). Factors predicting survival following alloSCT in patients with therapy-related AML and MDS: a multicenter study.. Bone Marrow Transplant, 58(7), 769-776. DOI Scopus3 WoS1 Europe PMC3
  2023	Shah, M. V., Tran, E. N. H., Shah, S., Chhetri, R., Baranwal, A., Ladon, D., . . . Hiwase, D. K. (2023). TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms. Blood Cancer Journal, 13(1), 51-1-51-9. DOI Scopus5 WoS2 Europe PMC4
  2023	Homan, C. C., Drazer, M. W., Yu, K., Lawrence, D. M., Feng, J., Arriola-Martinez, L., . . . Brown, A. L. (2023). Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41. Blood Advances, 7(20), 6092-6107. DOI Scopus8 Europe PMC6
  2023	Eadie, L. N., Rehn, J. A., Schutz, C. E., Heatley, S. L., Kutyna, M. M., Hiwase, D. K., . . . Yeung, D. T. (2023). Case report: Rare case of donor cell-derived T-cell acute lymphoblastic leukaemia in a female patient after receiving an allo-transplant from her male sibling. British Journal of Haematology, 203(2), 282-287. DOI
  2023	Sharplin, K., Proudman, W., Chhetri, R., Tran, E. N. H., Choong, J., Kutyna, M., . . . Hiwase, D. (2023). A Personalized Risk Model for Azacitidine Outcome in Myelodysplastic Syndrome and Other Myeloid Neoplasms Identified by Machine Learning Model Utilizing Real-World Data. Cancers, 15(16), 1-14. DOI Scopus1
  2023	Loo, S., Roberts, A. W., Anstee, N. S., Kennedy, G. A., He, S., Schwarer, A. P., . . . Wei, A. H. (2023). Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG. Blood, 142(23), 1960-1971. DOI Scopus2 WoS1
  2023	Fox, L. C., McQuilten, Z. K., Firkin, F., Fox, V., Badoux, X., Bajel, A., . . . Wood, E. M. (2023). The Australian Aplastic Anaemia and other Bone Marrow Failure Syndromes Registry. Best Practice and Research: Clinical Haematology, 36(4), 10 pages. DOI
  2023	Saygin, C., Roloff, G. W., Hahn, C. N., Chhetri, R., Gill, S. I., Elmariah, H., . . . Godley, L. A. (2023). Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies. Blood Advances, 7(4), 549-554. DOI Scopus21 WoS10 Europe PMC11
  2022	Kutyna, M. M., Kok, C. H., Lim, Y., Tran, E. N. H., Campbell, D., Paton, S., . . . Hiwase, D. K. (2022). A senescence stress secretome is a hallmark of therapy-related myeloid neoplasm stromal tissue occurring soon after cytotoxic exposure. Leukemia, 36(11), 2678-2689. DOI Scopus10 WoS4 Europe PMC8
  2022	Beckmann, K., Kearney, B. J., Yeung, D., Hiwase, D., Li, M., & Roder, D. M. (2022). Changes in five-year survival for people with acute leukaemia in South Australia, 1980-2016. Medical Journal of Australia, 216(6), 296-302. DOI Scopus4 WoS5 Europe PMC3
  2022	Shah, M. V., Chhetri, R., Dholakia, R., Kok, C. H., Gangat, N., Alkhateeb, H. B., . . . Hiwase, D. (2022). Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms. American Journal of Hematology, 97(8), 1013-1022. DOI Scopus5 WoS5 Europe PMC5
  2022	Baranwal, A., Hahn, C. N., Shah, M. V., & Hiwase, D. K. (2022). Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms. Current Hematologic Malignancy Reports, 17(6), 254-265. DOI Scopus7 WoS3 Europe PMC6
  2022	Selby, P. R., Warner, M. S., Peake, S. L., Bardy, P., Hiwase, D., Singhal, D., . . . Shakib, S. (2022). Optimising antifungal prophylaxis in allogeneic stem cell transplantation - a cohort study of two different approaches. Transplant Infectious Disease, 24(6), 1-11. DOI Europe PMC1
  2021	Ravandi, F., Roboz, G. J., Wei, A. H., Döhner, H., Pocock, C., Selleslag, D., . . . Dombret, H. (2021). Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial. Journal of Hematology and Oncology, 14(1), 14 pages. DOI Scopus10 WoS8 Europe PMC6
  2021	Samaraweera, S. E., Wang, P. P. S., Li, K. L., Casolari, D. A., Feng, J., Pinese, M., . . . D'Andrea, R. J. (2021). Childhood acute myeloid leukemia shows a high level of germline predisposition. Blood, 138(22), 2293-2298. DOI Scopus5 WoS5 Europe PMC5
  2021	Tiong, I. S., Dillon, R., Ivey, A., Kuzich, J. A., Thiagarajah, N., Sharplin, K. M., . . . Wei, A. H. (2021). Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia. Blood Advances, 5(23), 5107-5111. DOI Scopus20 WoS15 Europe PMC11
  2021	Singhal, D., Hahn, C. N., Feurstein, S., Wee, L. Y. A., Moma, L., Kutyna, M. M., . . . Hiwase, D. K. (2021). Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer. Leukemia, 35(11), 3245-3256. DOI Scopus34 WoS26 Europe PMC25
  2021	Sharplin, K., Wee, L. Y. A., Singhal, D., Edwards, S., Danner, S., Lewis, I., . . . Hiwase, D. K. (2021). Outcomes and health care utilization of older patients with acute myeloid leukemia.. Journal of geriatric oncology, 12(2), 243-249. DOI Scopus5 WoS4 Europe PMC5
  2021	Shanmuganathan, N., Pagani, I. S., Ross, D. M., Park, S., Yong, A. S., Braley, J. A., . . . Hughes, T. P. (2021). Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia. Blood, 137(9), 1196-1207. DOI Scopus49 WoS40 Europe PMC24
  2020	Cheok, K. P. L., Chhetri, R., Wee, L. Y. A., Friel, O., Pham, A., Salvi, A., . . . Hiwase, D. K. (2020). The burden of immune-mediated refractoriness to platelet transfusions in myelodysplastic syndromes. Transfusion, 60(10), 2192-2198. DOI Scopus10 WoS8 Europe PMC3
  2020	Brown, A. L., & Hiwase, D. K. (2020). What's germane in the germline? Finding clinically relevant germline variants in myeloid neoplasms from tumor only screening. Leukemia Research, 96, 3 pages. DOI Scopus3 WoS3 Europe PMC1
  2020	Marinelli, T., Wee, L. Y. A., Rowe, E., Chhetri, R., Friel, O., Higgins, G., . . . Hiwase, D. K. (2020). Respiratory Viruses Cause Late Morbidity in Recipients of Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 26(4), 782-788. DOI Scopus15 WoS10 Europe PMC6
  2020	Kuzmanovic, T., Patel, B. J., Sanikommu, S. R., Nagata, Y., Awada, H., Kerr, C. M., . . . Radivoyevitch, T. (2020). Genomics of therapy-related myeloid neoplasms. Haematologica, 105(3), E98-E101. DOI Scopus23 WoS19 Europe PMC15
  2020	Brown, A. L., Arts, P., Carmichael, C. L., Babic, M., Dobbins, J., Chong, C. -E., . . . Scott, H. S. (2020). RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML. Blood Advances, 4(6), 1131-1144. DOI Scopus89 WoS65 Europe PMC57
  2020	Molga, A., Wall, M., Chhetri, R., Wee, L. Y., Singhal, D., Edwards, S., . . . Hiwase, D. (2020). Comprehensive geriatric assessment predicts azacitidine treatment duration and survival in older patients with myelodysplastic syndromes. Journal of Geriatric Oncology, 11(1), 114-120. DOI Scopus31 WoS25 Europe PMC19
  2020	Molga, A., Wall, M., Wee, L. Y. A., Chhetri, R., Singhal, D., Singhal, N., . . . Hiwase, D. (2020). Screening for deficits using the G8 and VES-13 in older patients with Myelodysplastic syndromes.. Journal of geriatric oncology, 11(1), 128-130. DOI Scopus4 WoS4 Europe PMC2
  2020	Roberts, M. B., Bak, N., Wee, L. Y. A., Chhetri, R., Yeung, D. T., Lewis, I., & Hiwase, D. K. (2020). Clinical Effectiveness of Conjugate Pneumococcal Vaccination In Hematopoietic Stem Cell Transplant Recipients.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 26(2), 421-427. DOI Scopus10 WoS10 Europe PMC5
  2020	Brown, A. L., Hahn, C., Hiwase, D., Godley, L. A., & Scott, H. S. (2020). Correct application of variant classification guidelines in germline RUNX1 mutated disorders to assist clinical diagnosis. LEUKEMIA & LYMPHOMA, 61(1), 2 pages. DOI Scopus2 WoS2 Europe PMC1
  2019	Ho, P. J., Hiwase, D., Ramakrishna, R., Viiala, N., Solterbeck, A., Traficante, R., . . . Bowden, D. K. (2019). Cardiac and hepatic siderosis in myelodysplastic syndrome, thalassemia and diverse causes of transfusion-dependent anemia: The TIMES study. HemaSphere, 3(3), 11 pages. DOI Scopus7 WoS8 Europe PMC4
  2019	Singhal, D., Wee, L. Y. A., Kutyna, M. M., Chhetri, R., Geoghegan, J., Schreiber, A. W., . . . Hiwase, D. K. (2019). The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution. Leukemia, 33(12), 2842-2853. DOI Scopus41 WoS38 Europe PMC25
  2019	Shanmuganathan, N., Braley, J. A., Yong, A. S. M., Hiwase, D. K., Yeung, D. T., Ross, D. M., . . . Branford, S. (2019). Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission. Blood, 134(1), 85-89. DOI Scopus21 WoS19 Europe PMC11
  2019	Germing, U., Oliva, E. N., Hiwase, D., & Almeida, A. (2019). Treatment of Anemia in Transfusion-Dependent and Non-Transfusion-Dependent Lower-Risk MDS: Current and Emerging Strategies. HemaSphere, 3(6), 9 pages. DOI Scopus20 WoS17 Europe PMC11
  2019	Kenealy, M., Hertzberg, M., Benson, W., Taylor, K., Cunningham, I., Stevenson, W., . . . Seymour, J. F. (2019). Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia. HAEMATOLOGICA, 104(4), 700-709. DOI Scopus14 WoS12 Europe PMC5
  2019	Shanmuganathan, N., Branford, S., Hughes, T. P., & Hiwase, D. (2019). Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI. Blood Advances, 3(3), 370-374. DOI Scopus5 WoS4 Europe PMC2
  2019	Clucas, D. B., Fox, L. C., Wood, E. M., Hong, F. S., Gibson, J., Bajel, A., . . . Wood, E. (2019). Revisiting acquired aplastic anaemia: current concepts in diagnosis and management. INTERNAL MEDICINE JOURNAL, 49(2), 152-159. DOI Scopus11 WoS8 Europe PMC9
  2019	Chhetri, R., Wee, L. Y. A., Sinha, R., Kutyna, M. M., Pham, A., Stathopoulos, H., . . . Hiwase, D. K. (2019). Red cell autoimmunization and alloimmunization in myelodysplastic syndromes: Prevalence, characteristic and significance. Haematologica, 104(10), E451-E454. DOI Scopus14 WoS12 Europe PMC4
  2018	New-Tolley, J., Smith, C., Koszyca, B., Otto, S., Maundrell, A., Bardy, P., . . . Limaye, V. (2018). Inflammatory myopathies after allogeneic stem cell transplantation. Muscle and Nerve, 58(6), 790-795. DOI Scopus18 WoS15 Europe PMC4
  2018	Hiwase, D., & Ross, D. (2018). Success is built on failures: tackling the challenge of ponatinib failure. Leukemia and Lymphoma, 59(6), 1279-1281. DOI Scopus1 WoS1
  2018	Hiwase, D., Tan, P., D'Rozario, J., Taper, J., Powell, A., Irving, I., . . . Hughes, T. (2018). Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: results from the Phase IIIb ENESTswift study. Leukemia Research, 67, 109-115. DOI Scopus12 WoS9 Europe PMC5
  2018	Schwarer, A. P., Butler, J., Jackson, K., Beligaswatte, A., Martin, L., Kennedy, G., . . . Marlton, P. (2018). A Comparison of High-Dose Cytarabine during Induction Versus Consolidation Therapy in Newly Diagnosed AML. HemaSphere, 2(6), 8 pages. DOI Scopus2 WoS2 Europe PMC1
  2017	Singhal, D., Kutyna, M. M., Chhetri, R., Wee, L. Y. A., Hague, S., Nath, L., . . . Hiwase, D. K. (2017). Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome. Haematologica, 102(12), 2021-2029. DOI Scopus44 WoS31 Europe PMC16
  2017	Hiwase, D., Singhal, D., Strupp, C., Chhetri, R., Kutyna, M., Wee, L., . . . Germing, U. (2017). Dynamic assessment of RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patients. American Journal of Hematology, 92(6), 508-514. DOI Scopus26 WoS24 Europe PMC13
  2017	Hiwase, D. (2017). The only thing that is constant is change: The 2016 revision to the World Health Organisation classification of myelodysplastic syndrome. Leukemia Research, 57, 102-103. DOI
  2017	Shanmuganathan, N., Hiwase, D., & Ross, D. (2017). Treatment of chronic myeloid leukemia: assessing risk, monitoring response, and optimizing outcome. Leukemia and Lymphoma, 58(12), 2799-2810. DOI Scopus17 WoS17 Europe PMC9
  2017	Cheah, J., Hahn, C., Hiwase, D., Scott, H., & Brown, A. (2017). Myeloid neoplasms with germline DDX41 mutation. International Journal of Hematology, 106(2), 163-174. DOI Scopus72 WoS59 Europe PMC52
  2016	Dawar, S., Shahrin, N., Sladojevic, N., D'Andrea, R., Dorstyn, L., Hiwase, D., & Kumar, S. (2016). Impaired haematopoietic stem cell differentiation and enhanced skewing towards myeloid progenitors in aged caspase-2-deficient mice. Cell Death and Disease, 7(12), e2509-1-e2509-9. DOI Scopus22 WoS21 Europe PMC17
  2016	Nievergall, E., Reynolds, J., Kok, C., Watkins, D., Biondo, M., Busfield, S., . . . White, D. (2016). TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy. Leukemia, 30(6), 1263-1272. DOI Scopus38 WoS32 Europe PMC23
  2015	Hahn, C., Ross, D., Feng, J., Beligaswatte, A., Hiwase, D., Parker, W., . . . Scott, H. (2015). A tale of two siblings: two cases of AML arising from a single pre-leukemic DNMT3A mutant clone. Leukemia, 29(10), 2101-2104. DOI Scopus26 WoS23 Europe PMC22
  2015	Yeung, D., Osborn, M., White, D., Branford, S., Braley, J., Herschtal, A., . . . Hughes, T. (2015). TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood, 125(6), 915-923. DOI Scopus79 WoS67 Europe PMC46
  2015	Hahn, C., Venugopal, P., Scott, H., & Hiwase, D. (2015). Splice factor mutations and alternative splicing as drivers of hematopoietic malignancy. Immunological Reviews, 263(1), 257-278. DOI Scopus38 WoS33 Europe PMC32
  2015	Schafranek, L., Nievergall, E., Powell, J., Hiwase, D., Leclercq, T., Hughes, T., & White, D. (2015). Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia. Leukemia, 29(1), 76-85. DOI Scopus28 WoS27 Europe PMC23
  2014	Nievergall, E., Ramshaw, H., Yong, A., Biondo, M., Busfield, S., Vairo, G., . . . Hiwase, D. (2014). Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells. Blood, 123(8), 1218-1228. DOI Scopus83 WoS77 Europe PMC62
  2014	Hiwase, D. K., Hahn, C. N., Babic, M., Moore, S., Butcher, C. M., Kutyna, M. M., . . . Scott, H. S. (2014). Clonal Diversity of Recurrently Mutated Genes in Myelodysplastic Syndromes. BLOOD, 124(21), 3 pages.
  2013	Puccini, J., Shalini, S., Voss, A., Gatei, M., Wilson, C., Hiwase, D., . . . Kumar, S. (2013). Loss of caspase-2 augments lymphomagenesis and enhances genomic instability in Atm-deficient mice. Proceedings of the National Academy of Sciences of the United States of America, 110(49), 19920-19925. DOI Scopus60 WoS53 Europe PMC45
  2013	Hiwase, D., Saunders, V., Nievergall, E., Ross, D., White, D., & Hughes, T. (2013). Dasatinib targets chronic myeloid leukemia-CD34⁺ progenitors as effectively as it targets mature cells. Haematologica, 98(6), 896-900. DOI Scopus8 WoS9 Europe PMC7
  2013	White, D., Eadie, L., Saunders, V., Hiwase, D., & Hughes, T. (2013). Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells. Leukemia, 27(5), 1201-1204. DOI Scopus7 WoS7 Europe PMC6
  2013	Chow, A., Lee, C., Hiwase, D., To, L., & Horvath, N. (2013). Relapsed multiple myeloma: who benefits from salvage autografts?. Internal Medicine Journal, 43(2), 156-161. DOI Scopus14 WoS12 Europe PMC9
  2013	Schafranek, L., Nievergall, E., Powell, J., Hiwase, D., White, D., Hughes, T., & Leclercq, T. (2013). STAT5 is a critical component of the time-dependent sensitivity of CML cells to TKI treatment in a BCR-ABL-dependent, but JAK2-independent manner. Blood, 122(21), 2705. DOI WoS1
  2012	Hiwase, D. K., & Hughes, T. P. (2012). Sudden blast crisis in chronic myeloid leukemia treated with tyrosine kinase inhibitors. Leukemia and Lymphoma, 53(7), 1251-1252. DOI Scopus3 WoS1 Europe PMC1
  2011	To, L., Levesque, J., Herbert, K., Winkler, I., Bendall, L., Hiwase, D., . . . Lewis, I. (2011). Mobilisation strategies for normal and malignant cells. Pathology, 43(6), 547-565. DOI Scopus9 WoS7 Europe PMC5
  2011	Hiwase, D., Yeung, D., & White, D. (2011). Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients. Expert Review of Hematology, 4(3), 285-299. DOI Scopus6 WoS6 Europe PMC5
  2011	Foot, N., Leong, Y., Dorstyn, L., Dalton, H., Ho, K., Zhao, L., . . . Kumar, S. (2011). Ndfip1-deficient mice have impaired DMT1 regulation and iron homeostasis. Blood, 117(2), 638-646. DOI Scopus35 WoS33 Europe PMC29
  2010	Hiwase, D., White, D., Powell, J., Saunders, V., Zrim, S., Frede, A., . . . Hughes, T. (2010). Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors. Leukemia, 24(4), 771-778. DOI Scopus48 WoS42 Europe PMC33
  2010	Hiwase, D., White, D., Zrim, S., Saunders, V., Vaz de Melo, J., & Hughes, T. (2010). Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy. Leukemia, 24(3), 658-660. DOI Scopus26 WoS25 Europe PMC22
  2009	Hiwase, D., White, D., Saunders, V., Kumar, S., Melo, J., & Hughes, T. (2009). Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL<sup>+</sup> cells. Leukemia, 23(6), 1205-1206. DOI Scopus16 WoS15 Europe PMC11
  2008	Hiwase, D., Saunders, V., Hewett, D., Frede, A., Zrim, S., Dang, P., . . . White, D. (2008). Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clinical Cancer Research, 14(12), 3881-3888. DOI Scopus164 WoS145 Europe PMC121
  2008	Hiwase, D., Hiwase, S., Bailey, M., Bollard, G., & Schwarer, A. (2008). The role of stem cell mobilization regimen on lymphocyte collection yield in patients with multiple myeloma. Cytotherapy, 10(5), 507-517. DOI Scopus19 WoS16 Europe PMC14
  2008	Hiwase, D., Hiwase, S., Bailey, M., Bollard, G., & Schwarer, A. (2008). Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma. Biology of Blood and Marrow Transplantation, 14(1), 116-124. DOI Scopus74 WoS67 Europe PMC55
  2007	Hiwase, D. K., Bollard, G., Hiwase, S., Bailey, M., Muirhead, J., & Schwarer, A. P. (2007). Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma. Cytotherapy, 9(6), 539-547. DOI Scopus47 WoS45 Europe PMC35
  2002	Mohite, U., Pathare, A., Al Kindi, S., Hiwase, D., Vadakkepat, N., & Knox-Macaulay, H. (2002). Autoimmune haemolytic anaemia as the presenting manifestation of agnogenic myeloid metaplasia. Haematologia, 32(4), 495-499.
  2002	Knox-Macaulay, H. H. M., Hiwase, D., Nusrat, N., & Ganesh, A. (2002). Pseudotumour cerebri occurring before treatment of acute promyelocytic leukaemia with all-trans-retinoic acid (ATRA). Haematologia, 32(1), 81-85. DOI Scopus2 Europe PMC2
  2000	Ghosh, K., Mitra, S., & Hiwase, D. (2000). Choroidal infiltrates simulating fundal changes of acute leukemia during hematological recovery following high-dose chemotherapy in acute myelomonocytic leukemia in remission. American Journal of Hematology, 63(1), 42-45. DOI Scopus3 Europe PMC3
  2000	Ghosh, K., Daar, S., Hiwase, D., & Nusrat, N. (2000). Primary Pseudomonas meningitis in an adult, splenectomized, multitransfused thalassaemia major patient. Haematologia, 30(1), 69-72. DOI Scopus11 Europe PMC5
  2000	Ghosh, K., Hiwase, D., & Muirhead, D. (2000). Intense eosinophilia with abnormal ultrastructure as presenting manifestation of acute lymphoblastic leukemia. Haematologia, 30(2), 137-141. DOI
  2000	Ghosh, K., Khanduri, U., Hiwase, D., Venugopal, S., & Muirhead, D. (2000). Acute Myelomonocytic Leukaemia with Pseudo-Chediak-Higashi inclusions in leukaemic blasts report of an unusual case. Haematologia, 30(3), 229-234. DOI Scopus1
  2000	Kulkarni, K., Parikh, P. M., Hiwase, D. K., Pai, V. R., Gopal, R., Saikia, T. K., & Advani, S. H. (2000). Letter to editor (multiple letters). Indian Journal of Hematology and Blood Transfusion, 18(1), 22-23.
  1999	Ghosh, K., Muirhead, D., Christie, B., & Hiwase, D. (1999). Ultrastructural changes in peripheral blood neutrophils in a patient receiving ganciclovir for CMV pneumonitis following allogenic bone marrow transplantation. Bone Marrow Transplantation, 24(4), 429-431. DOI Scopus2 Europe PMC2

• Book Chapters

  Year	Citation
  2011	Hiwase, D. K., & Hughes, T. P. (2011). Therapy of Advanced-Stage and Resistant Chronic Myeloid Leukemia. In Leukemias: Principles and Practice of Therapy (pp. 281-295). Wiley. DOI
  2008	Hiwase, D., & Hughes, T. (2008). Monitoring response to therapy for patients with chronic myeloid leukemia. In Chronic Myeloproliferative Disorders (pp. 103-117).

• Conference Papers

  Year	Citation
  2020	Ravandi, F., Pocock, C., Selleslag, D., Montesinos, P., Sayar, H., Musso, M., . . . Dombret, H. (2020). Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 Maintenance Therapy in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Trial. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 20 (pp. S187-S188). CIG MEDIA GROUP, LP. WoS1
  2019	Cheok, K. P. L., Chhetri, R., Wee, L. Y. A., Salvi, A., Mcrae, S., Roxby, D. J., . . . Hiwase, D. K. (2019). The Burden of Clinically Significant Bleeding, Thrombocytopenia and Platelet Transfusions in Myelodysplastic Syndromes. In BLOOD Vol. 134 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY. DOI
  2019	Sharplin, K., Wee, L. Y. A., Edwards, S., Danner, S., Yong, A. S., Singhal, D., & Hiwase, D. (2019). Outcomes and Healthcare Utilization in Older Patients with Acute Myeloid Leukemia (AML). In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 19 (pp. S224). CIG MEDIA GROUP, LP. DOI
  2019	Singhal, D., Hahn, C. N., Moma, L. D., Wee, L. Y. A., Chhetri, R., Babic, M., . . . Hiwase, D. K. (2019). Deleterious Germline Variants, Especially in the DNA Repair Pathway, Are Common in Patients with Non-Related Multiple Cancers, One of Them Being Hematological Malignancy. In BLOOD Vol. 134 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY. DOI WoS1
  2019	Brown, A. L., Babic, M., Schreiber, A., Feng, J., Dobbins, J., Arts, P., . . . Scott, H. S. (2019). Familial Clustering of Hematological Malignancies: Harbingers of Wider Germline Cancer Susceptibility. In BLOOD Vol. 134 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY. DOI WoS1
  2019	Hahn, C. N., Babic, M., Brautigan, P. J., Venugopal, P., Phillips, K., Dobbins, J., . . . Scott, H. S. (2019). Australian Familial Haematological Cancer Study - Findings from 15 Years of Aggregated Clinical, Genomic and Transcriptomic Data. In BLOOD Vol. 134 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY. DOI WoS2
  2019	Molga, A., Wall, M., Chhetri, R., Wee, A., Singhal, D., Giri, P., . . . Hiwase, D. K. (2019). An Observational Study of the Prescribing Practices and Patient Reported Outcomes Measures in Older People with Myelodysplastic Syndrome. In BLOOD Vol. 134 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY. DOI
  2019	Unnikrishnan, A., Lim, X. Y., Joshi, S., Nunez, A. C., Vaughan, L., Pickford, R., . . . Pimanda, J. (2019). <i>In Vivo</i> Assessment of Intracellular Dynamics Comparing Injection Versus Oral Azacitidine in a Phase IIb Investigator Initiated Clinical Trial. In BLOOD Vol. 134 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY. DOI
  2019	Kutyna, M., Paton, S., Gronthos, S., & Hiwase, D. (2019). ABERRANT BONE MARROW MICROENVIRONMENT IN THERAPY RELATED MYELOID NEOPLASM. In EXPERIMENTAL HEMATOLOGY Vol. 76 (pp. E3-E4). ELSEVIER SCIENCE INC.
  2018	Shanmuganathan, N., Branford, S., Yong, A., Hiwase, D., Yeung, D., Ross, D., & Hughes, T. (2018). Predictors of Success in Treatment-Free Remission: A Single Centre Experience. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Vol. 18 (pp. S224). CIG MEDIA GROUP, LP. DOI
  2017	Shanmuganathan, N., Branford, S., Yeung, D., Hiwase, D. K., Yong, A. S. M., Ross, D. M., & Hughes, T. P. (2017). Cumulative Incidence of Treatment-Free Remission (TFR) for Patients with Chronic Myeloid Leukemia (CML): The Adelaide Experience. In BLOOD Vol. 130 (pp. 3 pages). Atlanta, GA: AMER SOC HEMATOLOGY.
  2017	Singhal, D., Kutyna, M. M., Chhetri, R., Wee, A., Hague, S., Nath, L., . . . Hiwase, D. K. (2017). Red Cell Alloimmunisation Is Associated with Development of Autoantibodies and Increased Red Cell Transfusion Requirements in Myelodysplastic Syndromes (MDS). In BLOOD Vol. 130 (pp. 3 pages). Atlanta, GA: AMER SOC HEMATOLOGY.
  2017	Al-Kali, A., Hiwase, D., Baer, M. R., Greenberg, P., Shortt, J., Collins, R., . . . Silverman, L. R. (2017). Relationship of bone marrow blast (BMBL) response to overall survival (OS) in a multicenter study of rigosertib (Rigo) in patients (pts) with myelodysplastic syndrome (MDS) with excess blasts progressing on or after treatment with a hypomethylating agent (HMA). In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 5 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS1
  2017	Singhal, D., Wee, A., Parker, W., Moore, S., Babic, M., Feng, J., . . . Hiwase, D. K. (2017). Presence of Rare Germline Variants in Fanconi Anaemia Pathway Genes Confers a Poor Prognosis Comparable to <i>TP53</i> Mutations in Therapy-Related Myeloid Neoplasms. In BLOOD Vol. 130 (pp. 3 pages). Atlanta, GA: AMER SOC HEMATOLOGY. WoS2
  2017	Hahn, C. N., Wee, A., Babic, M., Feng, J., Wang, P., Kutyna, M. M., . . . Scott, H. S. (2017). Duplication on Chromosome 14q Identified in Familial Predisposition to Myeloid Malignancies and Myeloproliferative Neoplasms. In BLOOD Vol. 130 (pp. 2 pages). Atlanta, GA: AMER SOC HEMATOLOGY. WoS2
  2016	Schwarer, A. P., Wight, J., Jackson, K., Beligaswatte, A. M., Butler, J. P., Kennedy, G., . . . Marlton, P. (2016). High-Dose Cytarabine (HiDAC) Improves the Cure Rate of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Is It Better to be Given As Induction Therapy or As Consolidation Therapy?. In BLOOD Vol. 128 (pp. 4 pages). San Diego, CA: AMER SOC HEMATOLOGY. DOI WoS23
  2016	Brown, A. L., Hahn, C. N., Carmichael, C., Wilkins, E., Babic, M., Chong, C. -E., . . . Scott, H. S. (2016). Expanded Phenotypic and Genetic Heterogeneity in the Clinical Spectrum of FPD-AML: Lymphoid Malignancies and Skin Disorders Are Common Features in Carriers of Germline <i>RUNX1</i> Mutations. In BLOOD Vol. 128 (pp. 6 pages). San Diego, CA: AMER SOC HEMATOLOGY. DOI
  2016	Shanmuganathan, N., Branford, S., Braley, J., Hiwase, D., Yeung, D. T., Ross, D. M., & Hughes, T. P. (2016). For Patients with Sustained MR4-MR4.5, Less Frequent Molecular Monitoring during the First 12 Months after Tyrosine Kinase Inhibitor Cessation Is Viable for Timely Detection of Loss of MMR. In BLOOD Vol. 128 (pp. 7 pages). San Diego, CA: AMER SOC HEMATOLOGY. DOI
  2016	Yeung, D. T., Osborn, M. P., White, D. L., Branford, S., Gerber, T., Butcher, B., . . . Hughes, T. P. (2016). Upfront Imatinib with Selective Early Switching to Nilotinib Leads to Excellent Achievement of Deep Molecular Response in Chronic Phase CML: 5 Year (Final) Analysis of the TIDEL-II Study. In BLOOD Vol. 128 (pp. 6 pages). San Diego, CA: AMER SOC HEMATOLOGY. DOI
  2016	Garcia-Manero, G., Fenaux, P., Al-Kali, A., Navada, S. C., Baer, M. R., Raza, A., . . . Silverman, L. R. (2016). Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). In BLOOD Vol. 128 (pp. 6 pages). San Diego, CA: AMER SOC HEMATOLOGY. DOI WoS9
  2016	Hiwase, D. K., Tan, P., D'Rozario, J., Taper, J., Powell, A. R., Irving, I., . . . Hughes, T. P. (2016). Efficacy and Safety of Nilotinib 300 Mg Twice Daily (BD) in Patients with CML in Chronic Phase (CML-CP) Who Are Intolerant to Prior BCR-ABL Tyrosine Kinase Inhibitors (TKIs): Results from the Randomized, Phase IIIb ENES Tswift Study. In BLOOD Vol. 128 (pp. 6 pages). San Diego, CA: AMER SOC HEMATOLOGY. DOI
  2016	Singhal, D., Strupp, C., Chhetri, R., Kutyna, M., Wee, L., Nath, S., . . . Germing, U. (2016). RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patients: analysis of South Australian and Dusseldorf MDS registries. In Proceedings of the 58th Annual Meeting and Exposition of the American Society of Hematology, as published in Blood Vol. 128 (pp. 1998). San Diego, CA: American Society of Hematology.
  2016	Singhal, D., Strupp, C., Chhetri, R., Kutyna, M. M., Wee, L. A., Nath, S. V., . . . Germing, U. (2016). RBC-Transfusion Dependency Improves the Prognostic Value of the Revised-IPSS in MDS Patients: Analysis of South Australian and Dusseldorf MDS Registries. In BLOOD Vol. 128 (pp. 6 pages). San Diego, CA: AMER SOC HEMATOLOGY.
  2016	Singhal, D., Wee, L. A., Parker, W. T., Moore, S., Babic, M., Feng, J., . . . Hiwase, D. K. (2016). The Frequency of Genetic Mutations in T-MN Is High and Comparable to Primary MDS but the Spectrum Is Different. In BLOOD Vol. 128 (pp. 5 pages). San Diego, CA: AMER SOC HEMATOLOGY. DOI
  2015	Singhal, D., Hague, S., Roxby, D., Wee, L. A., Lee, O. -L., Sinha, R., . . . Hiwase, D. K. (2015). RBC Alloimmunization Burden Is High in Regularly RBC-Transfused Myelodysplastic Syndrome (MDS) Patients: A Report from South Australian-MDS Registry. In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY.
  2015	Hahn, C. N., Babic, M., Schreiber, A. W., Kutyna, M. M., Wee, L. A., Brown, A. L., . . . Hiwase, D. (2015). Rare and Common Germline Variants Contribute to Occurrence of Myelodysplastic Syndrome. In BLOOD Vol. 126 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY. DOI WoS3
  2015	Hoi, P. J., Hiwase, D., Ramakrishna, A., Viiala, N., Ross, D. M., Zor, E., & Gervasio, O. L. (2015). Prevalence of Cardiac and H sis in Australian Patients with Transfusion-Dependent Anemias or No -Dependent Thalassemia, As Assessed By MRI (the TIMES study). In BLOOD Vol. 126 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY.
  2015	Hiwase, D., Hahn, C., Babic, M., Moore, S., Singhal, D., Kutyna, M., . . . Scott, H. (2015). MULTIPLE MUTATIONS IN THE SAME GENE SUGGEST CLONAL DIVERSITY AND IS ASSOCIATED WITH POOR PROGNOSIS IN MDS. In LEUKEMIA RESEARCH Vol. 39 (pp. S77-S78). Washington, DC: PERGAMON-ELSEVIER SCIENCE LTD. DOI
  2015	Hiwase, D., Moore, S., Kutyna, M., Fraser, R., Singhal, D., Chhetri, R., . . . Scott, H. (2015). SNP-MICROARRAY OF PERIPHERAL BLOOD-GRANULOCYTES DNA CAN DETECT CLONAL EVOLUTION IN MYELODYSPLASTIC SYNDROMES (MDS). In LEUKEMIA RESEARCH Vol. 39 (pp. S79-S80). Washington, DC: PERGAMON-ELSEVIER SCIENCE LTD. DOI
  2015	Kenealy, M., Benson, W., Stevenson, W., Eek, R., Zantomio, D., Cunningham, I., . . . Seymour, J. F. (2015). THE ADDITION OF LENALIDOMIDE TO AZACITIDINE ACHIEVES HIGHER RESPONSES BUT NO IMPROVEMENT IN TWELVE MONTH CLINICAL BENEFIT OR PFS; MAIN ANALYSIS AUSTRALIAN ALLG MDS4 TRIAL. In LEUKEMIA RESEARCH Vol. 39 (pp. S5). Washington, DC: PERGAMON-ELSEVIER SCIENCE LTD. DOI WoS3
  2015	Hiwase, D., Moore, S., Hahn, C., Kutyna, M., Van der Hoek, M., Fraser, R., . . . Scott, H. (2015). TARGETED MUTATION SEQUENCING AND SNP-MICRORRAY CAN IDENTIFY POOR PROGNOSTIC GROUP IN IPSS-LOWER RISK GROUP. In LEUKEMIA RESEARCH Vol. 39 (pp. S78-S79). Washington, DC: PERGAMON-ELSEVIER SCIENCE LTD. DOI
  2013	Hiwase, D. K., Kutyna, M. M., Chhetri, R., Howell, S., Harrison, P. B., Nath, S. V., . . . To, L. B. (2013). Transfusion Dependency Is Associated With Inferior Survival Even In Very Low and Low Risk IPSS-R Patients. In BLOOD Vol. 122 (pp. 2 pages). New Orleans, LA: AMER SOC HEMATOLOGY. DOI WoS4
  2011	Chow, A. W. S., Lee, C. H. S., Hiwase, D. K., To, L. B., & Horvath, N. (2011). Relapsed Multiple Myeloma: Who Benefits From Salvage Autografts?. In BLOOD Vol. 118 (pp. 1319). San Diego, CA: AMER SOC HEMATOLOGY.
  2011	Yeung, D. T., Osborn, M., White, D. L., Branford, S., Kornhauser, M., Slader, C., . . . Hughes, T. P. (2011). Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial. In BLOOD Vol. 118 (pp. 208). San Diego, CA: AMER SOC HEMATOLOGY. WoS1
  2011	Nievergall, E., White, D. L., Ramshaw, H., Lopez, A. F., Hughes, T. P., & Hiwase, D. K. (2011). Antibody-Targeting of IL-3 Receptor-α Increases the Susceptibility of CD34<SUP>+</SUP> CML Progenitors to Dasatinib-Induced Cell Death. In BLOOD Vol. 118 (pp. 1599). San Diego, CA: AMER SOC HEMATOLOGY. DOI WoS1
  2010	Yeung, D. T., Osborn, M., White, D. L., Branford, S., Haswell, L., Slader, C., . . . Hughes, T. (2010). Selective Escalation of Imatinib Therapy and Early Switching to Nilotinib In De Novo Chronic Phase CML Patients: Interim Results From the TIDEL-II Trial. In BLOOD Vol. 116 (pp. 96). Orlando, FL: AMER SOC HEMATOLOGY. DOI WoS10
  2010	Yeung, D., Osborn, M., White, D., Branford, S., Haswell, L., Slader, C., . . . Hughes, T. (2010). Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phase CML patients: interim results from the TIDELL-II trial. In Proceedings of 2010 American Society of Hematology conference (pp. 1-2). Florida.
  2010	Hiwase, D. K., Engler, J., Saunders, V., White, D. L., & Hughes, T. (2010). In Contrast to Imatinib, Dasatinib Intracellular Concentration In CML-CD34<SUP>+</SUP> Progenitors Is Not Significantly Different Than That Observed In CD34<SUP>-</SUP> Mature Cells.. In BLOOD Vol. 116 (pp. 517). Orlando, FL: AMER SOC HEMATOLOGY.
  2010	Hiwase, D. K., Eadie, L., Saunders, V., Hughes, T., & White, D. L. (2010). Proton Pump Inhibitors Augment Nilotinib and Dasatinib Mediated Bcr-Abl Kinase Inhibition.. In BLOOD Vol. 116 (pp. 1626-1627). Orlando, FL: AMER SOC HEMATOLOGY. WoS1
  2010	Hiwase, D. K., Eadie, L., Saunders, V., Hughes, T., & White, D. L. (2010). Proton Pump Inhibitors Augment Nilotinib and Dasatinib Mediated Bcr-Abl Kinase Inhibition. In Blood Vol. 116 (pp. 3991). American Society of Hematology. DOI
  2009	Hiwase, D. K., White, D. L., Powell, J. A., Saunders, V. A., Zrim, S., Frede, A., . . . Hughes, T. (2009). Blocking of Cytokine Survival Signals along with Intense Bcr-Abl Kinase Inhibition May Eradicate CML Progenitor Cells. In BLOOD Vol. 114 (pp. 1258-1259). New Orleans, LA: AMER SOC HEMATOLOGY.
  2008	Hiwase, D. K., White, D. L., Saunders, V. A., Melo, J. V., Kumar, S., & Hughes, T. P. (2008). Short-Term Intense Bcr-Abl Kinase Inhibition Is Adequate to Trigger Cell Death in CML Cell Lines but Not in CML-CD34+Cells Unless They Are Growth Factor Deprived. In BLOOD Vol. 112 (pp. 397). San Francisco, CA: AMER SOC HEMATOLOGY.
  2007	Hiwase, D. K., White, D. L., Saunders, V. A., Dang, P., Venables, A., Eadie, L., . . . Hughes, T. P. (2007). In contrast to imatinib, OCT-1 mediated influx has minimal impact on cellular uptake of dasatinib in CML patients at diagnosis. In BLOOD Vol. 110 (pp. 575A-576A). Atlanta, GA: AMER SOC HEMATOLOGY. WoS7
  2007	Hiwase, D. K., White, D. L., Saunders, V. A., Dang, P., Venables, A., Eadie, L., . . . Hughes, T. P. (2007). In Contrast to Imatinib, OCT-1 Mediated Influx Has Minimal Impact on Cellular Uptake of Dasatinib in CML Patients at Diagnosis.. In Blood Vol. 110 (pp. 1937). American Society of Hematology. DOI

• Conference Items

  Year	Citation
  2019	Hong, L. E., Singhal, D., Wee, A., Chhetri, R., Kutyna, M., Wechalekar, M., . . . Proudman, S. (2019). MUTATIONAL LANDSCAPE OF MYELODYSPLASTIC SYNDROME IN PATIENTS WITH AUTOIMMUNE RHEUMATOLOGICAL DISORDERS. Poster session presented at the meeting of ANNALS OF THE RHEUMATIC DISEASES. Madrid, SPAIN: BMJ PUBLISHING GROUP. DOI
  2019	Kutyna, M. M., Wee, A., Paton, S., Cakouros, D., Arthur, A., Chhetri, R., . . . Hiwase, D. K. (2019). Aberrant Bone Marrow Microenvironment in Therapy Related Myeloid Neoplasm (t-MN). Poster session presented at the meeting of BLOOD. Orlando, FL: AMER SOC HEMATOLOGY. DOI WoS2
  2018	Shanmuganathan, N., Branford, S., Yong, A. S. M., Hiwase, D. K., Yeung, D. T., Ross, D. M., & Hughes, T. P. (2018). The e13a2 BCR-ABL1 Transcript Is Associated with Higher Rates of Molecular Recurrence after Treatment-Free Remission Attempts: Retrospective Analysis of the Adelaide Cohort. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY. DOI WoS5
  2018	Molga, A., Wall, M., Chhetri, R., Wee, A., Singhal, D., Singhal, N., . . . Hiwase, D. K. (2018). Geriatric Assessment in Older People with Myelodysplasia Is Predictive of Azacitidine Therapy Completion and Survival: A Prospective Interventional Study at the Royal Adelaide Hospital. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY. DOI WoS2
  2018	Singhal, D., Wee, A., Kutyna, M. M., Babic, M., Chhetri, R., Parker, W., . . . Hiwase, D. K. (2018). Therapy-Related Myeloid Neoplasms (T-MN) and Primary MDS (PMDS) Patients with Very Low (VL) or Low (L) IPSS-R Score Share Clinical and Biological Characteristics and Have Similar Outcome. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY. DOI
  2018	Hong, L. E., Singhal, D., Wee, A., Chhetri, R., Wechalekar, M. D., Proudman, S., & Hiwase, D. K. (2018). The Mutation Profile of Myelodysplastic Syndrome Associated with Auto-Immune Rheumatological Disorders. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY. DOI
  2018	Pradhan, A., Chhetri, R., Wee, A., Malhotra, R., Singhal, D., Nelson, R., . . . Hiwase, D. K. (2018). Causative Organisms and Resistance Patterns of Infection in Patients with Myelodysplastic Syndrome (MDS): A 20 Year Retrospective Analysis. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY. DOI
  2018	Chhetri, R., Wee, A., Sinha, R., Kutyna, M. M., Gupta, S., Nath, L., . . . Hiwase, D. K. (2018). Red Cell Alloimmunisation Is Associated with Increased Red Cell Transfusion Requirements in Myelodysplastic Syndrome. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY. DOI WoS1
  2017	Singhal, D., Wee, L. A., Babic, M., Parker, W., Moore, S., Feng, J., . . . Hiwase, D. (2017). THERAPY RELATED MYELOID NEOPLASMS (T-MN) SHOW HIGH MUTATION FREQUENCY AND A SPECTRUM DIFFERENT FROM PRIMARY MDS. Poster session presented at the meeting of LEUKEMIA RESEARCH. Valencia, SPAIN: PERGAMON-ELSEVIER SCIENCE LTD. DOI
  2017	Singhal, D., Chhetri, R., Wee, L. A., Kutyna, M., Nath, S., & Hiwase, D. (2017). IRON CHELATION THERAPY IS ASSOCIATED WITH IMPROVED SURVIVAL IN LOWER RISK MDS. Poster session presented at the meeting of LEUKEMIA RESEARCH. Valencia, SPAIN: PERGAMON-ELSEVIER SCIENCE LTD. DOI
  2016	Singhal, D., Moore, S., Kutyna, M., Chhetri, R., Wee, L. A., Gray, J., . . . Hiwase, D. (2016). THERAPY RELATED MYELOID NEOPLASM FOLLOWING RADIOTHERAPY HAS HIGHER INCIDENCE OF POOR RISK CYTOGENETICS AND ARE ASSOCIATED WITH POOR SURVIVAL COMPARED TO DE NOVO MDS CASES. Poster session presented at the meeting of HAEMATOLOGICA. Copenhagen, DENMARK: FERRATA STORTI FOUNDATION.
  2016	Watts, S., Saunders, V., Wee, A., Kutyna, M., White, D. L., Hughes, T., & Hiwase, D. (2016). Understanding the mechanism of secondary resistance to Azacitidine in Myelodysplastic syndromes using the cell-line model MOLM-13. Poster session presented at the meeting of Poster Session. Adelaide, SA.
  2016	Watts, S., Wee, A., Saunders, V., Kutyna, M., White, D. L., Hughes, T., & Hiwase, D. (2016). Determining Mechanisms of Resistance to Azacitidine (Aza) in Myelodysplastic (MDS) Syndromes and Acute Myeloid Leukaemia (AML) using an in-vitro model. Poster session presented at the meeting of Poster Session. Melbourne, VIC.
  2016	Ho, P. J., Hiwase, D., Ramakrishna, R., Viiala, N., Ross, D., Zor, E., . . . Bowden, D. K. (2016). THE IMPACT OF CARDIAC AND HEPATIC MRI ASSESSMENT ON THE CLINICAL MANAGEMENT OF AUSTRALIAN PATIENTS WITH TRANSFUSION DEPENDENT ANEMIAS OR NON-TRANSFUSION-DEPENDENT THALASSEMIA IN THE TIMES STUDY. Poster session presented at the meeting of HAEMATOLOGICA. Copenhagen, DENMARK: FERRATA STORTI FOUNDATION.
  2014	Kenealy, M., Benson, W., Stevenson, W., Eek, R., Zantomio, D., Cunningham, I., . . . Seymour, J. F. (2014). THE ADDITION OF LENALIDOMIDE TO AZACITIDINE IN HIGHER RISK MDS IS DELIVERABLE WITH HIGHER RESPONSE RATES; FIRST ANALYSIS OF THE ALLG MDS4 RANDOMISED PHASE II STUDY. Poster session presented at the meeting of HAEMATOLOGICA. Milan, ITALY: FERRATA STORTI FOUNDATION.
  2014	Nievergall, E., Reynolds, J., Kok, C. H., Watkins, D., Biondo, M., Busfield, S. J., . . . Hughes, T. P. (2014). High plasma levels of TGF-α and IL-6 at diagnosis predict early molecular response failure and transformation in CML. Poster session presented at the meeting of Abstract of presentation to 56th ASH Annual Meeting, published in Blood. San Francisco, California: American Society of Hematology. DOI WoS1
  2014	Hiwase, D. K., Singhal, D., Chhetri, R., Kutyna, M. M., Harrison, P. B., Nath, S. V., . . . To, L. B. (2014). Inclusion of RBC-Transfusion Dependency Can Improve the Prognostic Value of Revised-IPSS in MDS Patients. Poster session presented at the meeting of BLOOD. San Francisco, CA: AMER SOC HEMATOLOGY.
  2013	Hiwase, D., Kutyna, M., Carr, T., Harrison, P., Melo, J. V., Bardy, P., & To, L. B. (2013). Transfusion dependency is associated with inferior outcome in very low- and low-risk IPSS-R patients. Poster session presented at the meeting of LEUKEMIA RESEARCH. PERGAMON-ELSEVIER SCIENCE LTD. DOI
  2013	Kenealy, M., Seymour, J. F., Benson, W., Stevenson, W., Eek, R., Zantomio, D., . . . Zannino, D. (2013). The combination of azacitidine and lenalidomide is deliverable without unexpected toxicity; interim safety results of the ALLG MDS4 randomised trial. Poster session presented at the meeting of LEUKEMIA RESEARCH. PERGAMON-ELSEVIER SCIENCE LTD. DOI WoS1
  2013	Hiwase, D., Yeung, D., Carne, L., Ross, D., Grigg, A., & Hughes, T. (2013). Hypercholesterolemia In Imatinib Intolerant/Resistant CML-CP Patients Treated With Nilotinib: A Retrospective Analysis. Poster session presented at the meeting of Blood. Amer Soc Hematology. WoS8
  2013	White, D. L., Schafranek, L., Nievergall, E., Powell, J. A., Hiwase, D., Leclercq, T., & Hughes, T. (2013). STAT5 is a critical component of the time-dependent sensitivity of CML cells to TKI treatment in a Bcr-Abl-dependent, but JAK2-independent manner.. Poster session presented at the meeting of American Society of Haematology. New Orleans, USA.
  2012	Amin, T., Elias, T., Hiwase, D., & Otto, S. (2012). SYSTEMIC MASTOCYTOSIS IS ASSOCIATED WITH MINIMAL CHANGE DISEASE. Poster session presented at the meeting of NEPHROLOGY. WILEY-BLACKWELL.
  2012	Nievergall, E., White, D. L., Yong, A. S. M., Ramshaw, H. S., Busfield, S. J., Vairo, G., . . . Hiwase, D. K. (2012). Effective Elimination of CML Progenitor and Stem Cells Through Combination of α-CD123 Antibody-Dependent Cell-Mediated Cytotoxicity and Tyrosine Kinase Inhibitor Treatment. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY. DOI
  2012	Schafranek, L., Nievergall, E., Powell, J. A., Hiwase, D. K., White, D. L., & Hughes, T. P. (2012). Commitment of CML Cells to Apoptotic Cell Death Depends On the Length of Exposure to Das and the Level of STAT5 Activity. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY. DOI WoS3
  2012	Yeung, D. T., Osborn, M. P., White, D. L., Branford, S., Kornhauser, M., Slader, C., . . . Hughes, T. P. (2012). Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY. DOI WoS8

I lead the MDS/AML research group in the South Australian Health and Medical Institute (SAHMRI) and supervise a research assistant, data manager, senior nurse, two PhD students, advanced trainee registrars and medical students. I am actively involved teaching medical students and was awarded “Best teacher of the year” by the University of Adelaide.

• Current Higher Degree by Research Supervision (University of Adelaide)

  Date	Role	Research Topic	Program	Degree Type	Student Load	Student Name
  2024	Principal Supervisor	The burden of cure: Secondary malignancy after allogeneic haematopoietic stem cell transplant	Doctor of Philosophy	Doctorate	Full Time	Miss Alia Elizabeth Cibich
  2023	Co-Supervisor	Novel Target Discovery for TP53 Mutated clonal Haematopoiesis	Doctor of Philosophy	Doctorate	Full Time	Mr Hossein Anani
  2023	Principal Supervisor	Role of Inherited and Acquired Genetic Changes in the Molecular Pathogenesis of Therapy-Related Myeloid Neoplasms	Doctor of Philosophy	Doctorate	Full Time	Dr Deepak Singhal
  2022	Co-Supervisor	A humanized monocyte model of TET2 mutated clonal hematopoiesis for noel target discovery	Doctor of Philosophy	Doctorate	Full Time	Miss Maha Kamel
  2021	Co-Supervisor	Deciphering the Role of New Adaptors in Regulation of Nedd4 Ubiquitin Ligases	Doctor of Philosophy	Doctorate	Full Time	Mr Ryan Daniel Norton
  2019	Co-Supervisor	Frailty in Patients with Haematological Malignancies	Doctor of Philosophy	Doctorate	Part Time	Dr Angela Teresa Molga

• Past Higher Degree by Research Supervision (University of Adelaide)

  Date	Role	Research Topic	Program	Degree Type	Student Load	Student Name
  2018 - 2022	Co-Supervisor	Evaluating the Role of Bone Marrow Microenvironment in the Pathogenesis of Therapy-related Myeloid Neoplasms	Doctor of Philosophy	Doctorate	Full Time	Mrs Monika Maria Kutyna

• Email: devendra.hiwase@adelaide.edu.au